Domené Horacio M, Scaglia Paula A, Jasper Héctor G
Centro de Investigaciones Endocrinológicas (CEDIE-CONICET), Hospital de Niños R. Gutiérrez, Buenos Aires, Argentina.
Pediatr Endocrinol Rev. 2010 Jun;7(4):339-46.
The acid-labile subunit (ALS) protein is a key component of the circulating 150-kDa IGF ternary complex. The main role of ALS is the extension of IGF-I half life by protecting it from degradation and preventing the passage of IGF-I to the extravascular compartment. In humans, complete ALS deficiency is characterized by severe reduction of IGF-I and IGFBP-3 that remain low after GH treatment, associated with mild growth retardation, much less pronounced than the IGF-I deficit. Pubertal delay in boys and insulin insensitivity are common findings. At least 21 patients with ALS deficiency have been described presenting 16 different homozygous or compound heterozygous inactivating mutations of the IGFALS gene. Although the effect of ALS deficiency on prenatal growth is still uncertain, postnatal growth is clearly affected, with the majority of the patients presenting a height between -2 to -3 SDS before and during puberty. In the assessment of a child with short stature ALS deficiency should be considered in those patients presenting: 1) a normal response to GH stimulation test, 2) low IGF-I levels associated with more profoundly reduced IGFBP-3 levels, 3) a mild growth retardation, apparently out of proportion to the degree of IGF-I and IGFBP-3 deficits, 4) lack of response to an IGF generation test and 5) insulin insensitivity. The relatively mild growth retardation in relation to the severe IGF-I deficit might be related to the preserved autocrine/paracrine action of locally produced IGF-I. The observation that in families of ALS deficient patients, heterozygous carriers for IGFALS gene mutations are shorter than their wild type relatives and the relatively high frequency of heterozygosity for this gene in children with idiopathic short stature suggests a requirement of normal levels of ALS for the attainment of maximal growth potential.
酸不稳定亚基(ALS)蛋白是循环中的150 kDa胰岛素样生长因子(IGF)三元复合物的关键组成部分。ALS的主要作用是通过保护IGF-I不被降解并防止其进入血管外腔室来延长IGF-I的半衰期。在人类中,完全ALS缺乏的特征是IGF-I和IGFBP-3严重降低,生长激素治疗后仍保持低水平,伴有轻度生长迟缓,远不如IGF-I缺乏明显。男孩青春期延迟和胰岛素抵抗是常见表现。至少已描述了21例ALS缺乏患者,他们存在IGFALS基因的16种不同纯合或复合杂合失活突变。尽管ALS缺乏对产前生长的影响仍不确定,但出生后生长明显受到影响,大多数患者在青春期前和青春期期间身高处于-2至-3 SDS之间。在评估身材矮小的儿童时,对于出现以下情况的患者应考虑ALS缺乏:1)对生长激素刺激试验反应正常;2)IGF-I水平低且IGFBP-3水平降低更明显;3)轻度生长迟缓,与IGF-I和IGFBP-3缺乏程度明显不成比例;4)对IGF生成试验无反应;5)胰岛素抵抗。与严重的IGF-I缺乏相比相对较轻的生长迟缓可能与局部产生的IGF-I保留的自分泌/旁分泌作用有关。在ALS缺乏患者家族中观察到,IGFALS基因突变的杂合携带者比其野生型亲属矮,以及该基因在特发性身材矮小儿童中的杂合频率相对较高,这表明需要正常水平的ALS才能实现最大生长潜能。